ArticleDiscover oncology2025
Yttrium90-TARE with or without chemotherapy may improve survival in patients with locally advanced unresectable intrahepatic cholangiocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe prognosis for patients with unresectable intrahepatic cholangiocarcinoma (iCCA) is poor. This retrospective observational cohort study evaluates survival outcomes in patients with unresectable iCCA after having received one of three different treatment plans offered at a tertiary referral center, chemotherapy alone, chemotherapy plus y90-TARE, or y90-TARE alone, and compares results with the published evidence. PATIENTS AND
methodsPatients seen at a tertiary center who received one of three treatments (chemotherapy only, chemotherapy plus y90-TARE, or y90-TARE only) were grouped as per their plan. Overall survival, resection rate, and progression free survival were compared.
resultsAmong the N = 56 patients included CT-only were younger (64 vs. 67.5 vs. 71yrs, p = 0.023) and higher stage III (78% vs. 29% vs. 32%, p = 0.001). More patients in the CT + y90 (36%) and y90-only (37%) groups were downstaged to resection than patients in the CT-only (4%) group; p = 0.014. Median OS for CT-only, CT + y90 and y90 were 13.9, 19.6, and 24.2 months, respectively; p = 0.076. In the adjusted model there was a trend toward improved OS and PFS for patients treated with y90-TARE compared to CT-only; the HR however remained below 1.
conclusionAlthough not statistically significant in the adjusted model, in univariate analysis patients with unresectable iCCA who received Y90-TARE in their treatment plan experienced better survival outcomes compared to those treated with CT-only.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.